CC
SABS icon

Caxton Corporation’s SAB Biotherapeutics SABS Stock Holding History

Caxton Corporation’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,527
Closed -$39.4K – 11
2025
Q4 		$39.4K Sell
10,527
-408
-4% -$1.34K 0.92% 10
2025
Q3 		$22K Buy
+10,935
New +$24.7K 0.1% 11

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caxton Corporation's SABS Position: Q1 2026 in Review

Caxton Corporation sold out of SAB Biotherapeutics (SABS) in Q1 2026, closing a stake of 10,527 shares — an estimated $39.4K sold.

Caxton Corporation first reported a position in SABS in Q3 2025 and held it in 2 quarters. The position peaked at $39.4K in Q4 2025. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Caxton Corporation reported no remaining SAB Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Corporation sold 10,527 SAB Biotherapeutics shares in Q1 2026, an estimated $39.4K.
  • Caxton Corporation first reported a position in SAB Biotherapeutics in Q3 2025 and held it in 2 quarters.
  • Caxton Corporation's SAB Biotherapeutics position peaked at $39.4K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.